Literature DB >> 8200933

Reduced concentration of serum growth hormone-binding protein in children with idiopathic short stature. National Cooperative Growth Study.

L M Carlsson1, K M Attie, P G Compton, R V Vitangcol, T J Merimee.   

Abstract

One possible explanation for the growth failure in children with idiopathic short stature (ISS) is reduced peripheral responsiveness to GH. In Laron syndrome, growth retardation is caused by GH resistance due to GH receptor (GH-R) defects, which are associated in most cases with absent or low serum concentrations of the GH-R-related GH-binding protein (GHBP). We tested the hypothesis that some children with ISS have reduced serum concentrations of GHBP and that this may reflect decreased sensitivity to GH. A ligand-mediated immunofunctional assay was used to measure biochemically active GHBP in serum from 1549 children, including 773 controls, 573 with ISS, 107 with GH deficiency (GHD), and 96 with Turner syndrome (TS). Ages ranged from 1-17 yr. Serum GHBP concentrations in children with GHD, ISS, and TS were converted to SD scores and compared to controls by analysis of variance. In male and female ISS subjects, approximately 90% had GHBP concentrations below the age- and sex-adjusted mean for controls, and 20% had GHBP concentrations below the normal range. The mean serum GHBP SD score was lower in both males and females with GHD (-0.6) or ISS (-1.2) than in controls (both P < 0.005). The mean for ISS males was significantly lower than that for GHD males (P < 0.0001). The mean GHBP SD score for girls with TS (-0.3) did not differ significantly from that of the control females. The decreased levels of serum GHBP in some children with idiopathic short stature suggest that these children could have a defect at the level of the GH-R.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8200933     DOI: 10.1210/jcem.78.6.8200933

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  9 in total

Review 1.  Growth hormone therapy in children with short stature: is bigger better or achievable?

Authors:  J A Germak
Journal:  Indian J Pediatr       Date:  1996 Sep-Oct       Impact factor: 1.967

Review 2.  Nonclassical GH Insensitivity: Characterization of Mild Abnormalities of GH Action.

Authors:  Helen L Storr; Sumana Chatterjee; Louise A Metherell; Corinne Foley; Ron G Rosenfeld; Philippe F Backeljauw; Andrew Dauber; Martin O Savage; Vivian Hwa
Journal:  Endocr Rev       Date:  2019-04-01       Impact factor: 19.871

Review 3.  Growth hormone/insulin-like growth factor system in children with chronic renal failure.

Authors:  Burkhard Tönshoff; Daniela Kiepe; Sonia Ciarmatori
Journal:  Pediatr Nephrol       Date:  2005-02-04       Impact factor: 3.714

4.  Serum growth hormone-binding protein is decreased in prepubertal children with idiopathic short stature.

Authors:  N Dávila; M Moreira-Andrés; J Alcañiz; B Barceló
Journal:  J Endocrinol Invest       Date:  1996-06       Impact factor: 4.256

5.  The Auxological and Biochemical Continuum of Short Children Born Small for Gestational Age (SGA) or with Normal Birth Size (Idiopathic Short Stature).

Authors:  Janina Caliebe; David D Martin; Michael B Ranke; Jan M Wit
Journal:  Int J Pediatr Endocrinol       Date:  2010-05-18

6.  Towards identification of molecular mechanisms of short stature.

Authors:  Lindsey A Waldman; Dennis J Chia
Journal:  Int J Pediatr Endocrinol       Date:  2013-11-20

Review 7.  Novel genetic cause of idiopathic short stature.

Authors:  Min Jae Kang
Journal:  Ann Pediatr Endocrinol Metab       Date:  2017-09-28

Review 8.  The continuum between GH deficiency and GH insensitivity in children.

Authors:  Martin O Savage; Helen L Storr; Philippe F Backeljauw
Journal:  Rev Endocr Metab Disord       Date:  2020-10-06       Impact factor: 6.514

Review 9.  Human Growth and Growth Hormone: From Antiquity to the Recominant Age to the Future.

Authors:  Evan Graber; Edward O Reiter; Alan D Rogol
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-05       Impact factor: 5.555

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.